Patents by Inventor Shuangni ZHAO

Shuangni ZHAO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240376081
    Abstract: Provided is a polymorph and application of a pyrimidine derivative and a pharmaceutically acceptable salt thereof. The polymorph and application of the pyrimidine derivative that is an A2A/A2B dual receptor antagonist having the chemical name 3-(4-amino-5-fluoro-6-(1-((6-(2-hydroxypropan-2-yl)pyridin-2-yl)methyl)-1H-1,2,3-triazol-4-yl)pyrimidine-2-yl)-2-methylbenzonitrile and the pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 14, 2022
    Publication date: November 14, 2024
    Inventors: Shuangni ZHAO, Taotao JIANG, Jibiao WANG, Tao TAO
  • Publication number: 20210395247
    Abstract: The present invention provides a BTK inhibitor, a pharmaceutically acceptable salt, a polymorph and an application thereof. Specifically, the present invention provides (R)-6-((1-acryloylpiperidin-3-yl)amino)-7-fluoro-4-((2-fluoro-4-morpholinophenyl)amino)-1,2-dihydro-3H-pyrrolo[3,4-c]pyridin-3-one, or the polymorph of a pharmaceutically acceptable salt thereof, and an application thereof. In addition, the present invention further discloses a pharmaceutical composition comprising the inhibitor and an application thereof.
    Type: Application
    Filed: March 18, 2020
    Publication date: December 23, 2021
    Inventors: Taotao JIANG, Jinjing LI, Shuangni ZHAO, Xia YAO
  • Publication number: 20210214358
    Abstract: Provided are a CDK4/6 inhibitor, a pharmaceutically acceptable salt thereof and a polymorph thereof, and the use thereof. In particular, provided are a polymorph of 2-cyclopropyl-N-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)-3-isopropyl-3,8-dihydroimidazo[4?,5?,4,5]cyclopentadieno[1,2-d]pyrimidin-5-amine and a pharmaceutically acceptable salt thereof, and the use thereof. In addition, further disclosed are a pharmaceutical composition of the compound and the use thereof.
    Type: Application
    Filed: April 23, 2019
    Publication date: July 15, 2021
    Inventors: Taotao JIANG, Jinjing LI, Shuangni ZHAO, Xia YAO
  • Publication number: 20210188813
    Abstract: The present invention provides an EZH2 inhibitor and pharmaceutically acceptable salts and polymorphic substances thereof, and application of the EZH2 inhibitor. Specifically, the present invention provides N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-ethyl-4-(ethyl((1S,4S)-4-(3-methoxyazetidin-1-yl)cyclohexyl)amino)-1-methyl-1H-indazole-6-carboxamide or polymorphic substances of pharmaceutically acceptable salts thereof, and application of N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-ethyl-4-(ethyl((1S,4S)-4-(3-methoxyazetidin-1-yl)cyclohexyl)amino)-1-methyl-1H-indazole-6-carboxamide. In addition, also disclosed are a pharmaceutical composition containing the inhibitor and application thereof.
    Type: Application
    Filed: April 23, 2019
    Publication date: June 24, 2021
    Inventors: Taotao JIANG, Shuangni ZHAO, Jinjing LI, Xia YAO